Prescott’s Med has achieved a significant milestone by acquiring Tenacore, a Costa Mesa, California-based company recognized for its depot-based medical device repair, parts supply, and technical support. This move strengthens Prescott’s Med’s position as a leading provider of surgical suite and specialty biomed solutions, supporting healthcare organizations in optimizing their biomed strategies.
Health Technology Insights: Collectly Launches Billie AI for Patient Eligibility and Benefits
Brian Straeb, Chief Executive Officer of Prescott’s Med, explained that the acquisition is more than a business transaction. He said it combines the expertise of two leading companies to form a nationwide partner for biomedical teams, enhancing service reliability, responsiveness, and overall customer experience across the country.
Founded in 2000, Tenacore has built a strong reputation for quality depot repair services, medical equipment, and parts distribution. Its “Quality at the Core” approach has made it a trusted partner for hospitals, in-house biomedical departments, and independent service organizations, providing reliable support and technical solutions.
Health Technology Insights: Saama Launches AI TLF Analyzer to Revolutionize Clinical Reports
Straeb emphasized that integrating Tenacore’s capabilities with Prescott’s Med’s operations allows the company to set a new standard of service for biomedical teams. He highlighted that the combined infrastructure, nationwide network of depot locations, and shared expertise will deliver unmatched support to healthcare providers.
The acquisition also expands Prescott’s Med’s depot service offerings, including repair and maintenance of infusion pumps, patient monitors, blenders, regulators, defibrillators, electrosurgical units, and other critical equipment. With enhanced inventory, broader service capabilities, and an extended support network, Prescott’s Med continues to position itself as a trusted partner for healthcare biomed teams nationwide.
Health Technology Insights: DESTINY-Lung06 Launches ENHERTU First-Line HER2+ NSCLC Trial
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
